nach oben

Cancer and Metastasis Reviews

Erschienen in:

06.12.2019

Immunotherapy in pediatric acute lymphoblastic leukemia

verfasst von: Hiroto Inaba, Ching-Hon Pui

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia (ALL) has improved to more than 90% in high-income countries. However, further increases in the intensity of conventional chemotherapy would be associated with significant adverse effects; therefore, novel approaches are necessary. The last decade has seen significant advances in targeted therapy with immunotherapy and molecular therapeutics, as well as advances in risk stratification for therapy based on somatic and germline genetic analysis and monitoring of minimal residual disease. For immunotherapy, the approval of antibody-based therapy (with blinatumomab in 2014 and inotuzumab ozogamicin in 2017) and T cell–based therapy (with tisagenlecleucel in 2017) by the US Food and Drug Administration has significantly improved the response rate and outcomes in patients with relapsed/refractory B-ALL. These strategies have also been tested in the frontline setting, and immunotherapy against a new ALL-associated antigen has been developed. Incorporating effective immunotherapy into ALL therapy would enable the intensity of conventional chemotherapy to be decreased and thereby reduce associated toxicity, leading to further improvement in survival and quality of life for patients with ALL.

Pui, C. H., Nichols, K. E., & Yang, J. J. (2019). Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nature Reviews Clinical Oncology, 16(4), 227–240.PubMed

Pui, C. H., Yang, J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A., Vora, A., Baruchel, A., Silverman, L. B., Schmiegelow, K., Escherich, G., Horibe, K., Benoit, Y. C., Izraeli, S., Yeoh, A. E., Liang, D. C., Downing, J. R., Evans, W. E., Relling, M. V., & Mullighan, C. G. (2015). Childhood acute lymphoblastic leukemia: progress through collaboration. Journal of Clinical Oncology, 33(27), 2938–2948.PubMedPubMedCentral

Jeha, S., Pei, D., Choi, J., Cheng, C., Sandlund, J. T., Coustan-Smith, E., et al. (2019). Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.19.01692.PubMedPubMedCentral

Pui, C. H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., et al. (2009). Treating childhood acute lymphoblastic leukemia without cranial irradiation. New England Journal of Medicine, 360(26), 2730–2741.

Teachey, D. T., & Pui, C. H. (2019). Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. The Lancet Oncology, 20(3), e142–e154.PubMed

Löffler, A., Kufer, P., Lutterbüse, R., Zettle, F., Daniel, P. T., Schwenkenbecher, J. M., et al. (2000). A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood, 95(96), 2098–2103.PubMed

Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., Einsele, H., Brandl, C., Wolf, A., Kirchinger, P., Klappers, P., Schmidt, M., Riethmüller, G., Reinhardt, C., Baeuerle, P. A., & Kufer, P. (2008). Tumor regression in cancer patients by very low doses of a T cell–engaging antibody. Science, 321(5891), 974–977.PubMed

Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., et al. (2011). Targeted therapy with the T-cell–engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Journal of Clinical Oncology, 29(18), 2493–2498.PubMed

Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M. E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., Stelljes, M., Schaich, M., Köhne-Volland, R., Brüggemann, M., Ottmann, O. G., Burmeister, T., Baeuerle, P. A., Nagorsen, D., Schmidt, M., Einsele, H., Riethmüller, G., Kneba, M., Hoelzer, D., Kufer, P., & Bargou, R. C. (2012). Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood, 120(26), 5185–5187.PubMed

10.

Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O’Brien, S., Bargou, R. C., et al. (2015). Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. The Lancet Oncology, 16(1), 57–66.PubMed

11.

Kantarjian, H. M., Stein, A. S., Bargou, R. C., Grande Garcia, C., Larson, R. A., Stelljes, M., Gökbuget, N., Zugmaier, G., Benjamin, J. E., Zhang, A., Jia, C., & Topp, M. S. (2016). Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer, 122(14), 2178–2185.PubMed

12.

Stein, A. S., Kantarjian, H., Gökbuget, N., Bargou, R., Litzow, M. R., Rambaldi, A., Ribera, J. M., Zhang, A., Zimmerman, Z., Zugmaier, G., & Topp, M. S. (2019). Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 25(8), 1498–1504.PubMed

13.

Przepiorka, D., Ko, C. W., Deisseroth, A., Yancey, C. L., Candau-Chacon, R., Chiu, H. J., Gehrke, B. J., Gomez-Broughton, C., Kane, R. C., Kirshner, S., Mehrotra, N., Ricks, T. K., Schmiel, D., Song, P., Zhao, P., Zhou, Q., Farrell, A. T., & Pazdur, R. (2015). FDA approval: blinatumomab. Clinical Cancer Research, 21(18), 4035–4039.PubMed

14.

Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J. M., et al. (2017). Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. New England Journal of Medicine, 376(9), 836–847.

15.

Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., et al. (2018). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood, 131(14), 1522–1531.PubMedPubMedCentral

16.

Brown, P. (2018). Blinatumomab for MRD⁺ B-ALL: The evidence strengthens. Blood, 131(14), 1497–1498.PubMed

17.

Jen, E. Y., Xu, Q., Schetter, A., Przepiorka, D., Shen, Y. L., Roscoe, D., et al. (2019). FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clinical Cancer Research, 25(2), 473–477.PubMed

18.

Martinelli, G., Boissel, N., Chevallier, P., Ottmann, O., Gökbuget, N., Topp, M. S., Fielding, A. K., Rambaldi, A., Ritchie, E. K., Papayannidis, C., Sterling, L. R., Benjamin, J., & Stein, A. (2017). Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. Journal of Clinical Oncology, 35(16), 1795–1802.PubMed

19.

Assi, R., Kantarjian, H., Short, N. J., Daver, N., Takahashi, K., Garcia-Manero, G., et al. (2017). Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome–positive leukemia. Clinical Lymphoma, Myeloma, and Leukemia, 17(12), 897–901.

20.

Klinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R. C., Topp, M. S., Gökbuget, N., Neumann, S., Goebeler, M., Viardot, A., Stelljes, M., Brüggemann, M., Hoelzer, D., Degenhard, E., Nagorsen, D., Baeuerle, P. A., Wolf, A., & Kufer, P. (2012). Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood, 119(26), 6226–6233.PubMed

21.

Zugmaier, G., Gökbuget, N., Klinger, M., Viardot, A., Stelljes, M., Neumann, S., Horst, H. A., Marks, R., Faul, C., Diedrich, H., Reichle, A., Brüggemann, M., Holland, C., Schmidt, M., Einsele, H., Bargou, R. C., & Topp, M. S. (2015). Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood, 126(24), 2578–2584.PubMedPubMedCentral

22.

von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Tripplett, T. M., Rizzari, C., et al. (2016). Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Journal of Clinical Oncology, 34(36), 4381–4389.

23.

Amgen (2019). Amgen announces positive results from two phase 3 BLINCYTO® (blinatumomab) studies in pediatric patients with relapsed acute lymphoblastic leukemia. https://www.amgen.com/media/news-releases/2019/09/amgen-announces-positive-results-from-two-phase-3-blincyto-blinatumomab-studies-in-pediatric-patients-with-relapsed-acute-lymphoblastic-leukemia/. Accessed 21 Nov 2019.

24.

Elitzur, S., Arad-Cohen, N., Barzilai-Birenboim, S., Ben-Harush, M., Bielorai, B., Elhasid, R., Feuerstein, T., Gilad, G., Gural, A., Kharit, M., Litichever, N., Nirel, R., Weinreb, S., Wolach, O., Toren, A., Izraeli, S., & Jacoby, E. (2019). Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: report from the Israeli Study Group of Childhood Leukemia. Pediatric Blood & Cancer, 66(10), e27898.

25.

Keating, A. K., Gossai, N., Phillips, C. L., Maloney, K., Campbell, K., Doan, A., Bhojwani, D., Burke, M. J., & Verneris, M. R. (2019). Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Advances, 3(13), 1926–1929.PubMedPubMedCentral

26.

Topp, M. S., Zimmerman, Z., Cannell, P., Dombret, H., Maertens, J., Stein, A., Franklin, J., Tran, Q., Cong, Z., & Schuh, A. C. (2018). Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood, 131(26), 2906–2914.PubMedPubMedCentral

27.

Prescribing information. Blincyto® (blinatumomab) injection.

28.

Jain, T., & Litzow, M. R. (2018). No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Hematology, American Society of Hematology Education Program, 2018(1), 25–34.

29.

Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., Fitzgerald, J. C., Aplenc, R., Gore, L., & Grupp, S. A. (2013). Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood, 121(26), 5154–5157.PubMedPubMedCentral

30.

Maschmeyer, G., De Greef, J., Mellinghoff, S. C., Nosari, A., Thiebaut-Bertrand, A., Bergeron, A., et al. (2019). Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections In Leukemia (ECIL). Leukemia, 33(4), 844–862.PubMedPubMedCentral

31.

Duell, J., Dittrich, M., Bedke, T., Mueller, T., Eisele, F., Rosenwald, A., et al. (2017). Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia, 31(10), 2181–2190.PubMedPubMedCentral

32.

Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., le Cesne, A., Zitvogel, L., & Chauffert, B. (2007). Metronomic cyclophosphamide regimen selectively depletes CD4⁺CD25⁺ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunology, Immunotherapy, 56(5), 641–648.PubMed

33.

Beyer, M., Kochanek, M., Darabi, K., Popov, A., Jensen, M., Endl, E., Knolle, P. A., Thomas, R. K., von Bergwelt-Baildon, M., Debey, S., Hallek, M., & Schultze, J. L. (2005). Reduced frequencies and suppressive function of CD4⁺CD25^hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood, 106(6), 2018–2025.PubMed

34.

Piccaluga, P. P., Arpinati, M., Candoni, A., Laterza, C., Paolini, S., Gazzola, A., Sabattini, E., Visani, G., & Pileri, S. A. (2011). Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leukemia & Lymphoma, 52(2), 325–327.

35.

Tedder, T. F., Tuscano, J., Sato, S., & Kehrl, J. H. (1997). CD22, a B lymphocyte–specific adhesion molecule that regulates antigen receptor signaling. Annual Review of Immunology, 15, 481–504.PubMed

36.

DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., et al. (2004). Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood, 103(5), 1807–1814.PubMed

37.

Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estely, E., Löwenberg, B., Dombret, H., et al. (2001). Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19(13), 3244–3254.PubMed

38.

Zein, N., Sinha, A. M., McGahren, W. J., & Ellestad, G. A. (1988). Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science, 240(4856), 1198–1201.PubMed

39.

Kantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M., et al. (2012). Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. The Lancet Oncology, 13(4), 403–411.PubMed

40.

Kantarjian, H., Thomas, D., Jorgensen, J., Kebriaei, P., Jabbour, E., Rytting, M., York, S., Ravandi, F., Garris, R., Kwari, M., Faderl, S., Cortes, J., Champlin, R., & O’Brien, S. (2013). Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer, 119(15), 2728–2736.PubMed

41.

DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., et al. (2017). Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Advances, 1(15), 1167–1180.PubMedPubMedCentral

42.

Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., et al. (2016). Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. New England Journal of Medicine, 375(8), 740–753.

43.

Leslie, M. (2017). ADC approval likely to spur more research. Cancer Discovery, 7(10), 1054–1055.

44.

Jabbour, E., Ravandi, F., Kebriaei, P., Huang, X., Short, N. J., Thomas, D., Sasaki, K., Rytting, M., Jain, N., Konopleva, M., Garcia-Manero, G., Champlin, R., Marin, D., Kadia, T., Cortes, J., Estrov, Z., Takahashi, K., Patel, Y., Khouri, M. R., Jacob, J., Garris, R., O’Brien, S., & Kantarjian, H. (2018). Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncology, 4(2), 230–234.PubMed

45.

Bhojwani, D., Sposto, R., Shah, N. N., Rodriguez, V., Yuan, C., Stetler-Stevenson, M., O’Brien, M. M., McNeer, J., Quereshi, A., Cabannes, A., Schlegel, P., Rossig, C., Dalla-Pozza, L., August, K., Alexander, S., Bourquin, J. P., Zwaan, M., Raetz, E. A., Loh, M. L., & Rheingold, S. R. (2019). Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia, 33(4), 884–892.PubMed

46.

Kantarjian, H. M., Su, Y., Jabbour, E. J., Bhattacharyya, H., Yan, E., Cappelleri, J. C., & Marks, D. I. (2018). Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer, 124(10), 2151–2160.PubMed

47.

Kantarjian, H. M., DeAngelo, D. J., Advani, A. S., Stelljes, M., Kebriaei, P., Cassday, R. D., et al. (2017). Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. The Lancet Haematology, 4(8), e387–e398.PubMed

48.

Guffroy, M., Falahatpisheh, H., Biddle, K., Kreeger, J., Obert, L., Walters, K., Goldstein, R., Boucher, G., Coskran, T., Reagan, W., Sullivan, D., Huang, C., Sokolowski, S., Giovanelli, R., Gerber, H. P., Finkelstein, M., & Khan, N. (2017). Liver microvascular injury and thrombocytopenia of antibody–calicheamicin conjugates in cynomolgus monkeys—mechanism and monitoring. Clinical Cancer Research, 23(7), 1760–1770.PubMed

49.

Taksin, A. L., Legrand, O., Raffoux, E., de Revel, T., Thomas, X., Contentin, N., Bouabdallah, R., Pautas, C., Turlure, P., Reman, O., Gardin, C., Varet, B., de Botton, S., Pousset, F., Farhat, H., Chevret, S., Dombret, H., & Castaigne, S. (2007). High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group. Leukemia, 21(1), 66–71.PubMed

50.

Wadleigh, M., Richardson, P. G., Zahrieh, D., Lee, S. J., Cutler, C., Ho, V., Alyea, E. P., Antin, J. H., Stone, R. M., Soiffer, R. J., & DeAngelo, D. (2003). Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102(5), 1578–8152.PubMed

51.

Jabbour, E. J., Sasaki, K., Ravandi, F., Short, N. J., Garcia-Manero, G., Daver, N., Kadia, T., Konopleva, M., Jain, N., Cortes, J., Issa, G. C., Jacob, J., Kwari, M., Thompson, P., Garris, R., Pemmaraju, N., Yilmaz, M., O’Brien, S. M., & Kantarjian, H. M. (2019). Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome–negative acute lymphoblastic leukemia: a propensity score analysis. Cancer, 125(15), 2579–2586.PubMed

52.

Jabbour, E., Sasaki, K., Ravandi, F., Huang, X., Short, N. J., Khouri, M., Kebriaei, P., Burger, J., Khoury, J., Jorgensen, J., Jain, N., Konopleva, M., Garcia-Manero, G., Kadia, T., Cortes, J., Jacob, J., Montalbano, K., Garris, R., O’Brien, S., & Kantarjian, H. M. (2018). Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage. Cancer, 124(20), 4044–4055.PubMed

53.

Paul, M. R., Wong, V., Aristizabal, P., & Kuo, D. J. (2019). Treatment of recurrent refractory pediatric pre-B acute lymphoblastic leukemia using inotuzumab ozogamicin monotherapy resulting in CD22 antigen expression loss as a mechanism of therapy resistance. Journal of Pediatric Hematology/Oncology, 41(8), e546–e549.PubMedPubMedCentral

54.

Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C. H., Geiger, T. L., & Campana, D. (2004). Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia, 18(4), 676–684.PubMed

55.

Brentjens, R. J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., et al. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical Cancer Research, 13(18 part 1), 5426–5435.PubMed

56.

Brudno, J. N., Somerville, R. P., Shi, V., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea-Banacloche, J. C., Pavletic, S. Z., Hickstein, D. D., Lu, T. L., Feldman, S. A., Iwamoto, A. T., Kurlander, R., Maric, I., Goy, A., Hansen, B. G., Wilder, J. S., Blacklock-Schuver, B., Hakim, F. T., Rosenberg, S. A., Gress, R. E., & Kochenderfer, J. N. (2016). Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. Journal of Clinical Oncology, 34(10), 1112–1121.PubMedPubMedCentral

57.

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., et al. (2013). Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368(16), 1509–1518.

58.

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Rheingold, S. R., Shen, A., Teachey, D. T., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507–1517.

59.

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., de Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A., & Grupp, S. A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439–448.

60.

Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., et al. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. The Lancet, 385(9967), 517–528.

61.

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., Roshal, M., Maslak, P., Davila, M., Brentjens, R. J., & Sadelain, M. (2018). Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New England Journal of Medicine, 378(5), 449–459.

62.

Pulsipher, M. A. (2018). Are CAR T cells better than antibody or HCT therapy in B-ALL? Hematology, American Society of Hematology Education Program, 2018(1), 16–24.

63.

Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 6(224), 224ra2.

64.

Summers, C., Annesley, C., Bleakley, M., Dahlberg, A., Jensen, M. C., & Gardner, R. (2018). Long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR T cell induced remission [abstract]. Blood, 132(supplement 1), 967.

65.

Talekar, M. K., Maude, S. L., Hucks, G. E., Motley, L. S., Callahan, C., White, C. M., et al. (2017). Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL) [abstract]. Journal of Clinical Oncology, 35(15 supplement), 10507.

66.

Chen, X., Wang, Y., Ruan, M., Li, J., Zhong, M., Li, Z., et al. (2019). Treatment of testicular relapse of B-cell acute lymphoblastic leukemia with CD19-specific chimeric antigen receptor T cells. Clinical Lymphoma, Myeloma & Leukemia. https://doi.org/10.1016/j.clml.2019.10.016.

67.

O’Leary, M. (2017). BLA Clinical Review Memorandum. https://www.fda.gov/media/107973/download. Accessed 21 Nov 2019.

68.

June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. New England Journal of Medicine, 379(1), 64–73.

69.

Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., White, J. C., Nazimuddin, F., Wertheim, G., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A. (2016). Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discovery, 6(6), 664–679.PubMedPubMedCentral

70.

Gardner, R., Ceppi, F., Rivers, J., Annesley, C., Summers, C., Taraseviciute, A., et al. (2019). Preemptive mitigation of CD19 CAR T cell cytokine release syndrome without attenuation of anti-leukemic efficacy. Blood. https://doi.org/10.1182/blood.2019001463.PubMedPubMedCentral

71.

Gust, J., Hay, K. A., Hanafi, L. A., Li, D., Myerson, D., Gonzalez-Cuyar, F., et al. (2017). Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discovery, 7(12), 1404–1419.PubMedPubMedCentral

72.

Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., Cross, J. R., Liu, H., Vachha, B., Chen, X., DeAngelis, L., Li, D., Bernal, Y., Gonen, M., Wendel, H. G., Sadelain, M., & Brentjens, R. J. (2018). Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discovery, 8(8), 958–971.PubMedPubMedCentral

73.

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Peggs, K., Pasquini, M., DiPersio, J., van den Brink, M., Komanduri, K. V., Grupp, S. A., & Neelapu, S. S. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625–638.PubMed

74.

Hill, J. A., Li, D., Hay, K. A., Green, M. L., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., Boeckh, M., & Turtle, C. J. (2018). Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood, 131(1), 121–130.PubMedPubMedCentral

75.

Laetsch, T. W., Maude, S. L., Milone, M. C., Davis, K. L., Krueger, J., Cardena, A. M., et al. (2018). False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. Blood, 131(23), 2596–2598.PubMedPubMedCentral

76.

Bhoj, V. G., Arhontoulis, D., Wertheim, G., Capobianchi, J., Callahan, C. A., Ellebrecht, C. T., et al. (2016). Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood, 128(3), 360–370.PubMedPubMedCentral

77.

Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., Kaplan, R. N., Patterson, G. H., Fry, T. J., Orentas, R. J., & Mackall, C. L. (2015). 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature Medicine, 21(6), 581–590.PubMedPubMedCentral

78.

Feucht, J., Sun, J., Eyquem, J., Ho, Y. J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., & Sadelain, M. (2019). Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine, 25(1), 82–88.PubMed

79.

Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015). CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 125(26), 4017–4023.PubMedPubMedCentral

80.

Ghorashian, S., Kramer, A. M., Onuoha, S., Wright, G., Bartram, J., Richardson, R., Albon, S. J., Casanovas-Company, J., Castro, F., Popova, B., Villanueva, K., Yeung, J., Vetharoy, W., Guvenel, A., Wawrzyniecka, P. A., Mekkaoui, L., Cheung, G. W., Pinner, D., Chu, J., Lucchini, G., Silva, J., Ciocarlie, O., Lazareva, A., Inglott, S., Gilmour, K. C., Ahsan, G., Ferrari, M., Manzoor, S., Champion, K., Brooks, T., Lopes, A., Hackshaw, A., Farzaneh, F., Chiesa, R., Rao, K., Bonney, D., Samarasinghe, S., Goulden, N., Vora, A., Veys, P., Hough, R., Wynn, R., Pule, M. A., & Amrolia, P. J. (2019). Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nature Medicine, 25(9), 1408–1414.PubMed

81.

Gardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., Hoglund, V., Lindgren, C., Oron, A. P., Li, D., Riddell, S. R., Park, J. R., & Jensen, M. C. (2017). Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood, 129(25), 3322–3331.PubMedPubMedCentral

82.

Maude, S. L., Barrett, D. M., Rheingold, S. R., Aplenc, R., Teachey, D. T., Callahan, C., et al. (2016). Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed/refractory acute lymphoblastic leukemia [abstract]. Blood, 128, 217.

83.

Rossig, C., Pule, M., Altvater, B., Saiagh, S., Wright, G., Ghorashian, S., Clifton-Hadley, L., Champion, K., Sattar, Z., Popova, B., Hackshaw, A., Smith, P., Roberts, T., Biagi, E., Dreno, B., Rousseau, R., Kailayangiri, S., Ahlmann, M., Hough, R., Kremens, B., Sauer, M. G., Veys, P., Goulden, N., Cummins, M., & Amrolia, P. J. (2017). Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia, 31(5), 1087–1095.PubMed

84.

Singh, N., Perazzelli, J., Grupp, S. A., & Barrett, D. M. (2016). Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Science Translational Medicine, 8(320), 320ra3.PubMed

85.

Sabatino, M., Hu, J., Sommariva, M., Gautam, S., Fellowes, V., Hocker, J. D., Dougherty, S., Qin, H., Klebanoff, C. A., Fry, T. J., Gress, R. E., Kochenderfer, J. N., Stroncek, D. F., Ji, Y., & Gattinoni, L. (2016). Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood, 128(4), 519–528.PubMedPubMedCentral

86.

Orlando, E. J., Han, X., Tribouley, C., Wood, P. A., Leary, R. J., Riester, M., Levine, J. E., Qayed, M., Grupp, S. A., Boyer, M., de Moerloose, B., Nemecek, E. R., Bittencourt, H., Hiramatsu, H., Buechner, J., Davies, S. M., Verneris, M. R., Nguyen, K., Brogdon, J. L., Bitter, H., Morrissey, M., Pierog, P., Pantano, S., Engelman, J. A., & Winckler, W. (2018). Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nature Medicine, 24(10), 1504–1506.PubMed

87.

Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., Martinez, N. M., Harrington, C. T., Chung, E. Y., Perazzelli, J., Hofmann, T. J., Maude, S. L., Raman, P., Barrera, A., Gill, S., Lacey, S. F., Melenhorst, J. J., Allman, D., Jacoby, E., Fry, T., Mackall, C., Barash, Y., Lynch, K. W., Maris, J. M., Grupp, S. A., & Thomas-Tikhonenko, A. (2015). Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discovery, 5(12), 1282–1295.PubMedPubMedCentral

88.

Jacoby, E., Nguyen, S. M., Fountaine, T. J., Welp, K., Gryder, B., Qin, H., et al. (2016). CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nature Communications, 7, 12320.PubMedPubMedCentral

89.

Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L. A., Finney, O., Smithers, H., Jensen, M. C., Riddell, S. R., Maloney, D. G., & Turtle, C. J. (2016). Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood, 127(20), 2406–2410.PubMedPubMedCentral

90.

Oberley, M. J., Gaynon, P. S., Bhojwani, D., Pulsipher, M. A., Gardner, R. A., Hiemenz, M. C., Ji, J., Han, J., O’Gorman, M. R. G., Wayne, A. S., & Raca, G. (2018). Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Pediatric Blood & Cancer, 65(9), e27265.

91.

Nagel, I., Bartels, M., Duell, J., Oberg, H. H., Ussat, S., Bruckmueller, H., Ottmann, O., Pfeifer, H., Trautmann, H., Gökbuget, N., Caliebe, A., Kabelitz, D., Kneba, M., Horst, H. A., Hoelzer, D., Topp, M. S., Cascorbi, I., Siebert, R., & Brüggemann, M. (2017). Hematopoietic stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood, 130(18), 2027–2031.PubMedPubMedCentral

92.

Rayes, A., McMasters, R. L., & O’Brien, M. M. (2016). Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatric Blood & Cancer, 63(6), 1113–1115.

93.

Balducci, E., Nivaggioni, V., Boudjarane, J., Bouriche, L., Rahal, I., Bernot, D., Alazard, E., Duployez, N., Grardel, N., Arnoux, I., Lafage-Pochitaloff, M., Michel, G., Nadel, B., & Loosveld, M. (2017). Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. Annals of Hematology, 96(9), 1579–1581.PubMed

94.

Cohen, A., Petsche, D., Grunberger, T., & Freedman, M. H. (1992). Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line. Leukemia Research, 16(8), 751–760.PubMed

95.

Alexander, T. B., Gu, Z., Iacobucci, I., Dickerson, K., Choi, J. K., Xu, B., Payne-Turner, D., Yoshihara, H., Loh, M. L., Horan, J., Buldini, B., Basso, G., Elitzur, S., de Haas, V., Zwaan, C. M., Yeoh, A., Reinhardt, D., Tomizawa, D., Kiyokawa, N., Lammens, T., de Moerloose, B., Catchpoole, D., Hori, H., Moorman, A., Moore, A. S., Hrusak, O., Meshinchi, S., Orgel, E., Devidas, M., Borowitz, M., Wood, B., Heerema, N. A., Carrol, A., Yang, Y. L., Smith, M. A., Davidsen, T. M., Hermida, L. C., Gesuwan, P., Marra, M. A., Ma, Y., Mungall, A. J., Moore, R. A., Jones, S. J. M., Valentine, M., Janke, L. J., Rubnitz, J. E., Pui, C. H., Ding, L., Liu, Y., Zhang, J., Nichols, K. E., Downing, J. R., Cao, X., Shi, L., Pounds, S., Newman, S., Pei, D., Guidry Auvil, J. M., Gerhard, D. S., Hunger, S. P., Inaba, H., & Mullighan, C. G. (2018). The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 562(7727), 373–379.PubMedPubMedCentral

96.

Hamieh, M., Dobrin, A., Cabriolu, A., van der Stegen, S. J. C., Giavridis, T., Mansilla-Soto, J., et al. (2019). CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature, 568(7750), 112–116.PubMedPubMedCentral

97.

Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., Nazimuddin, F., Bhoj, V. G., Orlando, E. J., Fry, T. J., Bitter, H., Maude, S. L., Levine, B. L., Nobles, C. L., Bushman, F. D., Young, R. M., Scholler, J., Gill, S. I., June, C. H., Grupp, S. A., Lacey, S. F., & Melenhorst, J. J. (2018). Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine, 24(10), 1499–1503.PubMedPubMedCentral

98.

Braig, F., Brandt, A., Goebeler, M., Tony, H. P., Kurze, A. K., Nollau, P., Bumm, T., Böttcher, S., Bargou, R. C., & Binder, M. (2017). Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood, 129(1), 100–104.PubMed

99.

Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D., Barrett, D. M., Wayne, A. S., Mackall, C. L., & Orentas, R. J. (2013). Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, 121(7), 1165–1174.PubMedPubMedCentral

100.

Qin, H., Cho, M., Haso, W., Zhang, L., Tasian, S. K., Oo, H. Z., Negri, G. L., Lin, Y., Zou, J., Mallon, B. S., Maude, S., Teachey, D. T., Barrett, D. M., Orentas, R. J., Daugaard, M., Sorensen, P. H., Grupp, S. A., & Fry, T. J. (2015). Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood, 126(5), 629–639.PubMedPubMedCentral

101.

Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., Shalabi, H., Fountaine, T. J., Shern, J. F., Majzner, R. G., Stroncek, D. F., Sabatino, M., Feng, Y., Dimitrov, D. S., Zhang, L., Nguyen, S., Qin, H., Dropulic, B., Lee, D. W., & Mackall, C. L. (2018). CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine, 24(1), 20–28.PubMed

102.

Ramakrishna, S., Highfill, S. L., Walsh, Z., Nguyen, S. M., Lei, H., Shern, J. F., Qin, H., Kraft, I. L., Stetler-Stevenson, M., Yuan, C. M., Hwang, J. D., Feng, Y., Zhu, Z., Dimitrov, D., Shah, N. N., & Fry, T. J. (2019). Modulation of target antigen density improves CAR T-cell functionality and persistence. Clinical Cancer Research, 25(17), 5329–5341.PubMedPubMedCentral

103.

Wang, N., Hu, X., Cao, W., Li, C., Xiao, Y., Cao, Y., et al. (2019). Efficacy and safety of CAR19/22 T-cell “cocktail” therapy in patients with refractory/ relapsed B-cell malignancies. Blood. https://doi.org/10.1182/blood.2019000017.PubMed

104.

Schneider, D., Xiong, Y., Wu, D., Nölle, V., Schmitz, S., Haso, W., et al. (2017). A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. Journal for Immunotherapy of Cancer, 5, 42.PubMedPubMedCentral

105.

Ruella, M., Barrett, D. M., Kenderian, S. S., Shestova, O., Hofmann, T. J., Perazelli, J., et al. (2016). Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. The Journal of Clinical Investigation, 126(10), 3814–3826.PubMedPubMedCentral

106.

Flowers, C. R., & Ramsey, S. D. (2018). What can cost-effectiveness analysis tell us about chimeric antigen receptor T-cell therapy for relapsed acute lymphoblastic leukemia? Journal of Clinical Oncology, 36(32), 3183–3185.

107.

Lin, J. K., Lerman, B. J., Barnes, J. I., Boursiquot, B. C., Tan, Y. J., Robinson, A. Q. L., et al. (2018). Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. Journal of Clinical Oncology, 36(32), 3192–3202.PubMed

108.

Whittington, M. D., McQueen, R. B., Ollendorf, D. A., Kumar, V. M., Chapman, R. H., Tice, J. A., et al. (2018). Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatrics, 172(12), 1161–1168.PubMedPubMedCentral

109.

Sarkar, R. R., Gloude, N. J., Schiff, D., & Murphy, J. D. (2019). Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. Journal of the National Cancer Institute, 111(7), 719–726.PubMed

110.

Laetsch, T. W., Myers, G. D., Baruchel, A., Dietz, A. C., Pulsipher, M. A., Bittencourt, H., et al. (2019). Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(19)30493-0.PubMedPubMedCentral

111.

Mamonkin, M., Rouce, R. H., Tashiro, H., & Brenner, M. K. (2015). A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood, 126(8), 983–992.PubMedPubMedCentral

112.

Sánchez-Martínez, D., Baroni, M. L., Gutierrez-Agüera, F., Roca-Ho, H., Blanch-Lombarte, O., González-García, S., Torrebadell, M., Junca, J., Ramírez-Orellana, M., Velasco-Hernández, T., Bueno, C., Fuster, J. L., Prado, J. G., Calvo, J., Uzan, B., Cools, J., Camos, M., Pflumio, F., Toribio, M. L., & Menéndez, P. (2019). Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood, 133(21), 2291–2304.PubMedPubMedCentral

113.

Gomes-Silva, D., Srinivasan, M., Sharma, S., Lee, C. M., Wagner, D. L., Davis, T. H., Rouce, R. H., Bao, G., Brenner, M. K., & Mamonkin, M. (2017). CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood, 130(3), 285–296.PubMedPubMedCentral

114.

Png, Y. T., Vinanica, N., Kamiya, T., Shimasaki, N., Coustan-Smith, E., & Campana, D. (2017). Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Advances, 1(25), 2348–2360.PubMedPubMedCentral

115.

Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., et al. (2017). Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Science Translational Medicine, 9(374), eaaj2013.PubMed

116.

Kantarjian, H., Ravandi, F., Short, N. J., Huang, X., Jain, N., Sasaki, K., Daver, N., Pemmaraju, N., Khoury, J. D., Jorgensen, J., Alvarado, Y., Konopleva, M., Garcia-Manero, G., Kadia, T., Yilmaz, M., Bortakhur, G., Burger, J., Kornblau, S., Wierda, W., DiNardo, C., Ferrajoli, A., Jacob, J., Garris, R., O’Brien, S., & Jabbour, E. (2018). Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome–negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. The Lancet Oncology, 19(2), 240–248.PubMed

117.

Chiaretti, S., Bassan, R., Vitale, A., Elia, L., Piciocchi, A., Ferrara, F., et al. (2019). A dasatinib-blinatumomab combination for the front-line treatment of adult Ph+ ALL patients. Preliminary results of the GIMEMA LAL2116 D-ALBA trial; on behalf of Gimema Acute Leukemia Working Party. HemaSphere, 3, 746.

Titel: Immunotherapy in pediatric acute lymphoblastic leukemia
verfasst von: Hiroto Inaba
Ching-Hon Pui
Publikationsdatum: 06.12.2019
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2019
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-019-09834-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Immunotherapy in pediatric acute lymphoblastic leukemia

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Pediatric diffuse intrinsic pontine glioma: where do we stand?

Compare and contrast: pediatric cancer versus adult malignancies

Biographies

Novel therapy for pediatric and adolescent kidney cancer

Wilms tumor, medulloblastoma, and rhabdomyosarcoma in adult patients: lessons learned from the pediatric experience

Joint-preservation surgery for pediatric osteosarcoma of the knee joint

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie